Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 46 of 58, showing 10 Applications out of 576 total, starting on record 451, ending on 460

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

451.

ECCT/16/07/01   VAC52150EBL4001
    A Multi-country, prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines AD26.ZEBOV and or/ MVA-BN-Filo   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Kenya medical Research Institute/Walter Reed Project Kombewa (Kisumu county)
3. Kenya medical Research Institute/Walter Reed Project Kombewa (Kericho county)
 
15-08-2016 View

452.

ECCT/16/06/02   A5263: A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings
     A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   
Principal Investigator(s)
1. Vincent Oliver Otieno
Site(s) in Kenya
1. Kisumu CRS (Kisumu county)
 
28-07-2016 View

453.

ECCT/16/06/01   P1115
    Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
KEMRI WALTER REED PROJECT KERICHO
 
25-07-2016 View

454.

ECCT/16/05/03   Clinical trial of neem & coconut oils for tungiasis
    Phase IIA, randomised controlled trial of a locally-made, herbal remedy (neem & coconut oil) for treatment of jiggers (Tunga penetrans)   
Principal Investigator(s)
1. Ulrike Fillinger
Site(s) in Kenya
Dabaso Tujengane CBO
 
28-03-2017 View

455.

ECCT/16/05/02   Monitoring Pre-exposure Prophylaxis for Young Adult women (MPYA)
    Next generation real-time monitoring for PrEP adherence in young Kenyan women   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. Thika Partners Study Clinic (Partners in Health Research and Development) (Kiambu county)
2. Partners in Prevention, Kisumu Site (Kisumu county)
 
07-09-2016 View

456.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
28-07-2016 View

457.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
14-07-2016 View

458.

ECCT/16/03/02   Infant TB Infection Prevention Study (“iTIPS”)
    Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants       
Principal Investigator(s)
1. Grace John-Stewart
Site(s) in Kenya
1. Kisumu East District Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Bondo sub-County Hospital (Kisumu county)
 
03-06-2016 View

459.

ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]   
Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
 
15-04-2016 View

460.

ECCT/16/02/05   PfSPZ Malaria Vaccine
    Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy   
Principal Investigator(s)
1. Martina Oneko
2. Mary J Hamel
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Wagai Health Center (Siaya county)
 
18-05-2016 View